[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
January 6, 1993

Delayed Trial of HIV Immune Globulin to Protect Infants of Infected Mothers Is Likely to Resume

JAMA. 1993;269(1):17. doi:10.1001/jama.1993.03500010021006

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


ABBOTT LABORATORIES has dropped its demands for immunity from liability and will no longer block a trial of a product that may prevent transmission of human immunodeficiency virus (HIV) from infected mothers to their babies (JAMA. 1992;268:1987-1992).

The North Chicago, Ill, company insists a threatened breach of contract suit had nothing to do with its decision.

Unfortunately, it may still be a full year from when a National Institutes of Health (NIH) sponsored multicenter trial was supposed to start (last July) to when it actually does.

All Rights Sold  Abbott sold all rights to its HIV Immune Globulin (HIVIG) to North American Biologicals Inc, of Miami, Fla, "including raw materials, some manufacturing equipment, the know-how, everything," as of November 4, says Abbott spokeswoman Traci Lance.North American Biologicals' chief executive officer, David Gury, says the agreement was actually made in September, "pending Abbott's dealing with their liability concerns. Finally, the